BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

293 related articles for article (PubMed ID: 17062843)

  • 1. Increased resting energy expenditure, fat oxidation, and food intake in patients with highly active antiretroviral therapy-associated lipodystrophy.
    Sutinen J; Yki-Järvinen H
    Am J Physiol Endocrinol Metab; 2007 Mar; 292(3):E687-92. PubMed ID: 17062843
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Adipose tissue inflammation and liver fat in patients with highly active antiretroviral therapy-associated lipodystrophy.
    Sevastianova K; Sutinen J; Kannisto K; Hamsten A; Ristola M; Yki-Järvinen H
    Am J Physiol Endocrinol Metab; 2008 Jul; 295(1):E85-91. PubMed ID: 18430964
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Calculating energy requirements for men with HIV/AIDS in the era of highly active antiretroviral therapy.
    Batterham MJ; Morgan-Jones J; Greenop P; Garsia R; Gold J; Caterson I
    Eur J Clin Nutr; 2003 Feb; 57(2):209-17. PubMed ID: 12571651
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Regulation of plasma PAI-1 concentrations in HAART-associated lipodystrophy during rosiglitazone therapy.
    Yki-Järvinen H; Sutinen J; Silveira A; Korsheninnikova E; Fisher RM; Kannisto K; Ehrenborg E; Eriksson P; Hamsten A
    Arterioscler Thromb Vasc Biol; 2003 Apr; 23(4):688-94. PubMed ID: 12615670
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Total energy expenditure and carbohydrate oxidation are increased in the human immunodeficiency virus lipodystrophy syndrome.
    Kosmiski LA; Kuritzkes DR; Sharp TA; Hamilton JT; Lichtenstein KA; Mosca CL; Grunwald GK; Eckel RH; Hill JO
    Metabolism; 2003 May; 52(5):620-5. PubMed ID: 12759894
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Adipokines and highly active antiretroviral therapy related lipodystrophy: clinical study of 52 cases].
    Tao MM; Zhang L; Qiu ZF; Xie J; Han Y; Yu W; Li M; Li TS
    Zhonghua Yi Xue Za Zhi; 2009 Apr; 89(13):867-71. PubMed ID: 19671283
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pronounced lipoatrophy in HIV-infected men receiving HAART for more than 6 years compared with the background population.
    Hansen AB; Lindegaard B; Obel N; Andersen O; Nielsen H; Gerstoft J
    HIV Med; 2006 Jan; 7(1):38-45. PubMed ID: 16313291
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Energy expenditure, substrate oxidation, and body composition in subjects with chronic alcoholism: new findings from metabolic assessment.
    Addolorato G; Capristo E; Greco AV; Stefanini GF; Gasbarrini G
    Alcohol Clin Exp Res; 1997 Sep; 21(6):962-7. PubMed ID: 9309302
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The metabolic syndrome, an epidemic among HIV-infected patients on HAART.
    Jevtović DJ; Dragović G; Salemović D; Ranin J; Djurković-Djaković O
    Biomed Pharmacother; 2009 Jun; 63(5):337-42. PubMed ID: 18996676
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The effect of rosiglitazone on insulin sensitivity, beta cell function, bone mineral density, and body composition in hiv-positive patients on highly-active antiretroviral therapy (HAART).
    Schindler K; Rieger A; Tura A; Gmeinhardt B; Touzeau-Römer V; Haider D; Pacini G; Ludvik B
    Horm Metab Res; 2009 Jul; 41(7):573-9. PubMed ID: 19322744
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Increased systemic and adipose tissue cytokines in patients with HIV-associated lipodystrophy.
    Johnson JA; Albu JB; Engelson ES; Fried SK; Inada Y; Ionescu G; Kotler DP
    Am J Physiol Endocrinol Metab; 2004 Feb; 286(2):E261-71. PubMed ID: 14532165
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Highly active antiretroviral therapy-induced lipodystrophy has minor effects on human immunodeficiency virus-induced changes in lipolysis, but normalizes resting energy expenditure.
    van der Valk M; Reiss P; van Leth FC; Ackermans MT; Endert E; Romijn JA; Heijligenberg R; Sauerwein H
    J Clin Endocrinol Metab; 2002 Nov; 87(11):5066-71. PubMed ID: 12414873
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Intramyocellular lipid accumulation and reduced whole body lipid oxidation in HIV lipodystrophy.
    Luzi L; Perseghin G; Tambussi G; Meneghini E; Scifo P; Pagliato E; Del Maschio A; Testolin G; Lazzarin A
    Am J Physiol Endocrinol Metab; 2003 Feb; 284(2):E274-80. PubMed ID: 12388139
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Short-term energy restriction reduces resting energy expenditure in patients with HIV lipodystrophy and hypermetabolism.
    Kosmiski LA; Bessesen DH; Stotz SA; Koeppe JR; Horton TJ
    Metabolism; 2007 Feb; 56(2):289-95. PubMed ID: 17224345
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Increased mitochondrial DNA content in peripheral blood lymphocytes from HIV-infected patients with lipodystrophy.
    Cossarizza A; Riva A; Pinti M; Ammannato S; Fedeli P; Mussini C; Esposito R; Galli M
    Antivir Ther; 2003 Aug; 8(4):315-21. PubMed ID: 14518701
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effects of medroxyprogesterone acetate on food intake, body composition, and resting energy expenditure in patients with advanced, nonhormone-sensitive cancer: a randomized, placebo-controlled trial.
    Simons JP; Schols AM; Hoefnagels JM; Westerterp KR; ten Velde GP; Wouters EF
    Cancer; 1998 Feb; 82(3):553-60. PubMed ID: 9452274
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Low-dose growth hormone and human immunodeficiency virus-associated lipodystrophy syndrome: a pilot study.
    Andersen O; Haugaard SB; Flyvbjerg A; Andersen UB; Ørskov H; Madsbad S; Nielsen JO; Iversen J
    Eur J Clin Invest; 2004 Aug; 34(8):561-8. PubMed ID: 15305891
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Uridine supplementation for the treatment of antiretroviral therapy-associated lipoatrophy: a randomized, double-blind, placebo-controlled trial.
    Sutinen J; Walker UA; Sevastianova K; Klinker H; Häkkinen AM; Ristola M; Yki-Järvinen H
    Antivir Ther; 2007; 12(1):97-105. PubMed ID: 17503753
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Update on HIV/HAART associated morphologic and metabolic abnormalities.
    Falutz J
    Forum Nutr; 2003; 56():158-62. PubMed ID: 15806844
    [No Abstract]   [Full Text] [Related]  

  • 20. [The influence of long-term nucleotide reverse transcriptase inhibitors on lipids metabolism in HIV/AIDS patients].
    Su YB; Xie J; Han Y; Qiu ZF; Li YL; Song XJ; Yu W; Li TS
    Zhonghua Nei Ke Za Zhi; 2012 Nov; 51(11):859-62. PubMed ID: 23291022
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.